FDA Expands Approval of Influenza Treatment to Post-Exposure Prevention
WASHINGTON, D.C. — The U.S. Food and Drug Administration has expanded the approved indication for Xofluza (baloxavir marboxil) to include post-exposure prevention of influenza (flu) for patients 12 years of …
Read More